OrbiMed’s Spyre Therapeutics SYRE Stock Holding History

OrbiMed’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-71,889	Closed	-$521K	–	136
2023 Q1	$521K	Hold	71,889	–	–	0.01%	120
2022 Q4	$809K	Hold	71,889	–	–	0.02%	113
2022 Q3	$945	Hold	71,889	–	–	0.02%	129
2022 Q2	$908	Sell	71,889 -46,356	-39%	-$1.62M	0.02%	141
2022 Q1	$6.8M	Hold	118,245	–	–	0.11%	111
2021 Q4	$14M	Sell	118,245 -42,376	-26%	-$6.69M	0.18%	102
2021 Q3	$31.9M	Hold	160,621	–	–	0.35%	74
2021 Q2	$27.9M	Hold	160,621	–	–	0.28%	84
2021 Q1	$31.8M	Hold	160,621	–	–	0.3%	80
2020 Q4	$31.6M	Hold	160,621	–	–	0.28%	80
2020 Q3	$28.5M	Hold	160,621	–	–	0.36%	72
2020 Q2	$37.1M	Buy	160,621 +46,000	+40%	+$8.76M	0.52%	55
2020 Q1	$13.4M	Hold	114,621	–	–	0.22%	80
2019 Q4	$21.9M	Hold	114,621	–	–	0.31%	63
2019 Q3	$22M	Buy	114,621 +28,000	+32%	+$5.45M	0.42%	56
2019 Q2	$14.8M	Hold	86,621	–	–	0.23%	80
2019 Q1	$17.4M	Hold	86,621	–	–	0.27%	79
2018 Q4	$16.2M	Hold	86,621	–	–	0.3%	75
2018 Q3	$20.7M	Buy	86,621 +12,000	+16%	+$2.8M	0.25%	88
2018 Q2	$19.7M	Buy	74,621 +15,840	+27%	+$3.9M	0.24%	93
2018 Q1	$14.6M	Hold	58,781	–	–	0.18%	92
2017 Q4	$7.95M	Hold	58,781	–	–	0.1%	109
2017 Q3	$7.24M	Hold	58,781	–	–	0.07%	114
2017 Q2	$5.66M	Hold	58,781	–	–	0.06%	111
2017 Q1	$10.9M	Buy	58,781 +4,372	+8%	+$617K	0.12%	92
2016 Q4	$5.92M	Hold	54,409	–	–	0.08%	109
2016 Q3	$8.72M	Hold	54,409	–	–	0.1%	104
2016 Q2	$6.61M	Buy	+54,409	New	+$10.4M	0.07%	107

Other funds holding SYRE

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

OrbiMed's SYRE Position: Q2 2023 in Review

OrbiMed sold out of Spyre Therapeutics (SYRE) in Q2 2023, closing a stake of 71,889 shares — an estimated $521K sold.

OrbiMed first reported a position in SYRE in Q2 2016 and held it in 28 quarters. The position peaked at $37.1M in Q2 2020. 43 funds tracked by Wall St. Rank hold SYRE as of Q2 2023.

OrbiMed reported no remaining Spyre Therapeutics position as of Q2 2023 after selling out during the quarter.
OrbiMed sold 71,889 Spyre Therapeutics shares in Q2 2023, an estimated $521K.
OrbiMed first reported a position in Spyre Therapeutics in Q2 2016 and held it in 28 quarters.
OrbiMed's Spyre Therapeutics position peaked at $37.1M in Q2 2020.
43 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2023.

Based on OrbiMed's 13F filing for Q2 2023, filed 14 Aug 2023.